PPT1 and cancer: identified PPT1 is the molecular target of a novel chloroquine derivative, the DC661; they found that knockout of PPT1 in several cancer cell lines using CRISPR-Cas9 editing resulted in significant impairment of tumor growth similar to that observed with DC661 treatment, which supported the tumor driver role of PPT1 in cancer (45, 46).